Mapping similarities in mTOR pathway perturbations in mouse lupus nephritis models and human lupus nephritis
Tóm tắt
Treatment with sirolimus, a mammalian target of rapamycin (mTOR) inhibitor, has been shown to be efficacious in the MRL/lpr and NZB × NZW F1 mouse models of lupus nephritis, indicating a critical role for the mTOR pathway in both models. This type of demonstration of efficacy in animal models is usually a pre-requisite for advancement into clinical development. However, efficacy in an animal model often has not translated to the desired activity in the clinic. Therefore, a more profound understanding of the mechanistic similarities and differences between various animal models and human diseases is highly desirable. Transcriptional profiling was performed on kidneys from mice with lupus nephritis; from mice who had efficacious drug treatment; and from mice before they developed nephritis. Analysis of variance with false discovery rate adjusted to p < 0.05 and an average fold change of two or more was used to identify transcripts significantly associated with disease and response to therapy. Pathway analyses (using various bioinformatics tools) were carried out to understand the basis for drug efficacy in the mouse model. The relevance in human lupus of the pathways identified in the mouse model was explored using information from several databases derived from the published literature. We identified a set of nephritis-associated genes in mouse kidney. Expression of the majority of these returned to asymptomatic levels on sirolimus treatment, confirming the correlation between expression levels and symptoms of nephritis. Network analysis showed that many of these nephritis genes are known to interact with the mTOR pathway. This led us to ask what human diseases are linked to the mTOR pathway. We constructed the mTOR pathway interactome consisting of proteins that interact with members of the mTOR pathway and identified a strong association between mTOR pathway genes and genes reported in the literature as being involved in human lupus. Our findings implicate the mTOR pathway as a critical contributor to human lupus. This broad pathway-based approach to understanding the similarities in, and differences between, animal models and human diseases may have broader utility.
Tài liệu tham khảo
Schroder NW, Maurer M: The role of innate immunity in asthma: leads and lessons from mouse models. Allergy. 2007, 62: 579-590. 10.1111/j.1398-9995.2007.01386.x.
Sena E, Worp van der HB, Howells D, Macleod M: How can we improve the pre-clinical development of drugs for stroke?. Trends Neurosci. 2007, 30: 433-439. 10.1016/j.tins.2007.06.009.
Sena E, Wheble P, Sandercock P, Macleod M: Systematic review and meta-analysis of the efficacy of tirilazad in experimental stroke. Stroke. 2007, 38: 388-394. 10.1161/01.STR.0000254462.75851.22.
Zosky GR, Larcombe AN, White OJ, Burchell JT, Janosi TZ, Hantos Z, Holt PG, Sly PD, Turner DJ: Ovalbumin-sensitized mice are good models for airway hyperresponsiveness but not acute physiological responses to allergen inhalation. Clin Exp Allergy. 2008, 38: 829-838. 10.1111/j.1365-2222.2007.02884.x.
Zosky GR, Sly PD: Animal models of asthma. Clin Exp Allergy. 2007, 37: 973-988. 10.1111/j.1365-2222.2007.02740.x.
Bertsias G, Ioannidis JP, Boletis J, Bombardieri S, Cervera R, Dostal C, Font J, Gilboe IM, Houssiau F, Huizinga T, Isenberg D, Kallenberg CG, Khamashta M, Piette JC, Schneider M, Smolen J, Sturfelt G, Tincani A, van Vollenhoven R, Gordon C, Boumpas DT, Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics: EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis. 2008, 67: 195-205. 10.1136/ard.2007.070367.
Rahman A, Isenberg DA: Systemic lupus erythematosus. N Engl J Med. 2008, 358: 929-939. 10.1056/NEJMra071297.
Mason L, Berden J: Pathogenic factors for the development of lupus nephritis. Lupus. 2008, 17: 251-255. 10.1177/0961203307088250.
Boumpas DT: Lupus nephritis. Nephrol Dial Transplant. 2001, 16 (Suppl 6): 55-57.
Aringer M, Smolen JS: Cytokine expression in lupus kidneys. Lupus. 2005, 14: 13-18. 10.1191/0961203305lu2053oa.
Baudino L, Azeredo da Silveira S, Nakata M, Izui S: Molecular and cellular basis for pathogenicity of autoantibodies: lessons from murine monoclonal autoantibodies. Springer Semin Immunopathol. 2006, 28: 175-184. 10.1007/s00281-006-0037-0.
Haas C, Ryffel B, Le Hir M: IFN-gamma is essential for the development of autoimmune glomerulonephritis in MRL/Ipr mice. J Immunol. 1997, 158: 5484-5491.
Miyake K, Nakashima H, Akahoshi M, Inoue Y, Nagano S, Tanaka Y, Masutani K, Hirakata H, Gondo H, Otsuka T, Harada M: Genetically determined interferon-gamma production influences the histological phenotype of lupus nephritis. Rheumatology (Oxford). 2002, 41: 518-524. 10.1093/rheumatology/41.5.518.
Santiago-Raber ML, Laporte C, Reininger L, Izui S: Genetic basis of murine lupus. Autoimmun Rev. 2004, 3: 33-39. 10.1016/S1568-9972(03)00062-4.
Foster MH: Relevance of systemic lupus erythematosus nephritis animal models to human disease. Semin Nephrol. 1999, 19: 12-24.
Reilly CM, Gilkeson GS: Use of genetic knockouts to modulate disease expression in a murine model of lupus, MRL/lpr mice. Immunol Res. 2002, 25: 143-153. 10.1385/IR:25:2:143.
Liu J, Karypis G, Hippen KL, Vegoe AL, Ruiz P, Gilkeson GS, Behrens TW: Genomic view of systemic autoimmunity in MRLlpr mice. Genes Immun. 2006, 7: 156-168. 10.1038/sj.gene.6364286.
Shlomchik MJ, Craft JE, Mamula MJ: From T to B and back again: positive feedback in systemic autoimmune disease. Nat Rev Immunol. 2001, 1: 147-153. 10.1038/35100573.
Hutloff A, Buchner K, Reiter K, Baelde HJ, Odendahl M, Jacobi A, Dorner T, Kroczek RA: Involvement of inducible costimulator in the exaggerated memory B cell and plasma cell generation in systemic lupus erythematosus. Arthritis Rheum. 2004, 50: 3211-3220. 10.1002/art.20519.
Ramos-Barron A, Pinera-Haces C, Gomez-Alamillo C, Santiuste-Torcida I, Ruiz JC, Buelta-Carrillo L, Merino R, de Francisco AL, Arias M: Prevention of murine lupus disease in (NZBxNZW)F1 mice by sirolimus treatment. Lupus. 2007, 16: 775-781. 10.1177/0961203307081401.
Warner LM, Adams LM, Sehgal SN: Rapamycin prolongs survival and arrests pathophysiologic changes in murine systemic lupus erythematosus. Arthritis Rheum. 1994, 37: 289-297. 10.1002/art.1780370219.
Lui S, Yung S, Tsang R, Zhang F, Chan K, Tam S, Chan T: Rapamycin prevents the development of nephritis in lupus-prone NZB/W F1 mice. Lupus. 2008, 17: 305-313. 10.1177/0961203307088289.
Chiang GG, Abraham RT: Targeting the mTOR signaling network in cancer. Trends Mol Med. 2007, 13: 433-442. 10.1016/j.molmed.2007.08.001.
Brunet M, Campistol JM, Diekmann F, Guillen D, Millan O: T-cell function monitoring in stable renal transplant patients treated with sirolimus monotherapy. Mol Diagn Ther. 2007, 11: 247-256.
Sarbassov DD, Ali SM, Sabatini DM: Growing roles for the mTOR pathway. Curr Opin Cell Biol. 2005, 17: 596-603. 10.1016/j.ceb.2005.09.009.
MacDonald AS: A worldwide, phase III, randomized, controlled, safety and efficacy study of a sirolimus/cyclosporine regimen for prevention of acute rejection in recipients of primary mismatched renal allografts. Transplantation. 2001, 71: 271-280. 10.1097/00007890-200101270-00019.
GEO – Gene Expression Omnibus. [http://www.ncbi.nlm.nih.gov/geo]
Reiner A, Yekutieli D, Benjamini Y: Identifying differentially expressed genes using false discovery rate controlling procedures. Bioinformatics. 2003, 19: 368-375. 10.1093/bioinformatics/btf877.
Tian L, Greenberg SA, Kong SW, Altschuler J, Kohane IS, Park PJ: Discovering statistically significant pathways in expression profiling studies. Proc Natl Acad Sci USA. 2005, 102: 13544-13549. 10.1073/pnas.0506577102.
Alperovich G, Rama I, Lloberas N, Franquesa M, Poveda R, Gomà M, Herrero-Fresneda I, Cruzado JM, Bolaños N, Carrera M, Grinyó JM, Torras J: New immunosuppresor strategies in the treatment of murine lupus nephritis. Lupus. 2007, 16: 18-24. 10.1177/0961203306073136.
He L, Sun Y, Takemoto M, Norlin J, Tryggvason K, Samuelsson T, Betsholtz C: The glomerular transcriptome and a predicted protein-protein interaction network. J Am Soc Nephrol. 2008, 19: 260-268. 10.1681/ASN.2007050588.
Peterson KS, Huang JF, Zhu J, D'Agati V, Liu X, Miller N, Erlander MG, Jackson MR, Winchester RJ: Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest. 2004, 113: 1722-1733.
Raught B, Gingras AC, Sonenberg N: The target of rapamycin (TOR) proteins. Proc Natl Acad Sci USA. 2001, 98: 7037-7044. 10.1073/pnas.121145898.
Rotig A, Munnich A: Genetic features of mitochondrial respiratory chain disorders. J Am Soc Nephrol. 2003, 14: 2995-3007. 10.1097/01.ASN.0000095481.24091.C9.
Berger SP, Daha MR: Complement in glomerular injury. Semin Immunopathol. 2007, 29: 375-384. 10.1007/s00281-007-0090-3.
Berger SP, Daha MR: Complement in glomerular nephritis. Semin Immunopathol. 2007, 29: 375-384. 10.1007/s00281-007-0090-3.
Haxhinasto S, Mathis D, Benoist C: The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med. 2008, 205: 565-574. 10.1084/jem.20071477.
Qu Y, Zhang B, Zhao L, Liu G, Ma H, Rao E, Zeng C, Zhao Y: The effect of immunosuppressive drug rapamycin on regulatory CD4+CD25+Foxp3+T cells in mice. Transpl Immunol. 2007, 17: 153-161. 10.1016/j.trim.2007.01.002.
Strauss L, Whiteside TL, Knights A, Bergmann C, Knuth A, Zippelius A: Selective survival of naturally occurring human CD4+CD25+Foxp3+ regulatory T cells cultured with rapamycin. J Immunol. 2007, 178: 320-329.
Keever-Taylor CA, Browning MB, Johnson BD, Truitt RL, Bredeson CN, Behn B, Tsao A: Rapamycin enriches for CD4(+) CD25(+) CD27(+) Foxp3(+) regulatory T cells in ex vivo-expanded CD25-enriched products from healthy donors and patients with multiple sclerosis. Cytotherapy. 2007, 9: 144-157. 10.1080/14653240601145223.
Kappos L, Barkhof F, Desmet A: The effect of oral temsirolimus on new magnetic resonance imaging scan lesions, brain atrophy, and the number of relapses in multiple sclerosis; results from a randomized, controlled clinical trial. J Neurol. 2005, 252 ((Supplement 2);S46 (abstract)): II/46-
Neuhaus O, Kieseier BC, Hartung HP: Immunosuppressive agents in multiple sclerosis. Neurotherapeutics. 2007, 4: 654-660. 10.1016/j.nurt.2007.08.003.
Dowling RJ, Zakikhani M, Fantus IG, Pollak M, Sonenberg N: Metformin inhibits mammalian target of rapamycin-dependent translation initiation in breast cancer cells. Cancer Res. 2007, 67: 10804-10812. 10.1158/0008-5472.CAN-07-2310.
Penfornis A, Kury-Paulin S: Immunosuppressive drug-induced diabetes. Diabetes Metab. 2006, 32: 539-546.
Battaglia M, Stabilini A, Migliavacca B, Horejs-Hoeck J, Kaupper T, Roncarolo MG: Rapamycin promotes expansion of functional CD4+CD25+FOXP3+ regulatory T cells of both healthy subjects and type 1 diabetic patients. J Immunol. 2006, 177: 8338-8347.
Foroncewicz B, Mucha K, Paczek L, Chmura A, Rowinski W: Efficacy of rapamycin in patient with juvenile rheumatoid arthritis. Transpl Int. 2005, 18: 366-368. 10.1111/j.1432-2277.2004.00070.x.
Tsang CK, Qi H, Liu LF, Zheng XF: Targeting mammalian target of rapamycin (mTOR) for health and diseases. Drug Discov Today. 2007, 12: 112-124. 10.1016/j.drudis.2006.12.008.
Faivre S, Kroemer G, Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 2006, 5: 671-688. 10.1038/nrd2062.
ClinicalTrial.gov, a service of the National Insitutes of Health. [http://clinicaltrials.gov]
Fernandez D, Bonilla E, Mirza N, Niland B, Perl A: Rapamycin reduces disease activity and normalizes T cell activation-induced calcium fluxing in patients with systemic lupus erythematosus. Arthritis Rheum. 2006, 54: 2983-2988. 10.1002/art.22085.
Sirolimus therapy for idopathic and lupus membranous nephropathy. [http://clinicaltrials.gov/ct2/show/NCT00050713]